Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis
Sign Up to like & getrecommendations! Published in 2024 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-024-01763-x
Abstract: Temozolomide (TMZ) represents a standard-of-care chemotherapeutic agent in glioblastoma (GBM). However, the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma. Although specific innovative approaches, such as immunotherapy, have shown… read more here.
Keywords: resistance; suppression itpkb; glioblastoma; tmz resistance ... See more keywords